Good news for doctors and patients with prostate cancer, of course, because researchers from Harvard in the United States have found a way to test whether the prostate cancer were categorized as malignant or not. This is clearly a much-anticipated progress and medical experts who had been applying genetic tests in diagnosing prostate cancer.
With this new genetic test, medical experts will easily decide between malignant prostate cancer requiring immediate handling and slow moving so that the tumor did not endanger lives if it is allowed.
Today, many men who have been diagnosed with prostate cancer treated with radiation or chemotherapy, even though the cancer was not malignant, so no harm category. While there is also a cancer that has metastasized, which spreads out from the prostate gland, and is usually life-threatening cancer.
"For the first time we've done tests on a mouse. If you take a gene, you will experience metastases and when the gene was restored, you will not experience metastases," said Karen Cichowski, author of the study results is also an assistant professor at Brigham and Women's Hospital, Harvard.
"It appears these conditions triggered by one of these genes, which promote metastasis."
He also said that a number of studies of prostate cancer have shown the same effect. "We have used this method in many cases the tumor, and we find that this will be deregulated in prostate cancer with more advanced stage."
These findings certainly can encourage prostate cancer treatment is better, because the molecule whose production is governed by these genes can be targets of drug therapy, Cichowski said.
Molecule called EZH2 are enzymes, and enzymes are usually always the potential for targeted therapy. According Cichowski, today many companies are developing inhibitors EZH2.
Actually this way is also done by Jer-Tsong Hsieh. Lecturer of pathology and urology at the University of Texas Southwestern Medical Center, Dallas, was researching a group of genes that are related to prostate cancer in 2002.
"We complement each other, our findings are very similar. I am a biologist examines cells and proteins, while Cichowski gene approach," Hsieh said, commenting on the findings of Harvard researchers.
Even Hsieh-led group is currently conducting research to develop a substance used in a chemical reaction to detect the enzyme.
Other prostate cancer genes researchers are Dr. Arul Chinnaiyan, professor of pathology and urology at the University of Michigan.
Research conducted Chinnaiyan of the recently published showing a link why EZH2 mechanistic trigger on cancer metastasis.
"It's quite interesting because there are a lot of interest in the world of biotechnology in developing inhibitors EZH2," Chinnaiyan added.
"Chinnaiyan has shown that there are genes for EZH2 in advanced prostate cancer," said Cichowski. "Hsieh indicated that the two genes in this genetic test is the target of EZH2 and can be attenuated by EZH2. This is one of the 250 genes targeted by EZH2. We have shown that in rat gene are the main target of EZH2 in prostate cancer."
DAB2IP named this gene is suppressed in prostate cancer, and the pressure level is correlated with cancer aggressiveness.
This is the first study that clearly shows not only genes but also the flow of metastasis in prostate cancer.
With this new genetic test, medical experts will easily decide between malignant prostate cancer requiring immediate handling and slow moving so that the tumor did not endanger lives if it is allowed.
Today, many men who have been diagnosed with prostate cancer treated with radiation or chemotherapy, even though the cancer was not malignant, so no harm category. While there is also a cancer that has metastasized, which spreads out from the prostate gland, and is usually life-threatening cancer.
"For the first time we've done tests on a mouse. If you take a gene, you will experience metastases and when the gene was restored, you will not experience metastases," said Karen Cichowski, author of the study results is also an assistant professor at Brigham and Women's Hospital, Harvard.
"It appears these conditions triggered by one of these genes, which promote metastasis."
He also said that a number of studies of prostate cancer have shown the same effect. "We have used this method in many cases the tumor, and we find that this will be deregulated in prostate cancer with more advanced stage."
These findings certainly can encourage prostate cancer treatment is better, because the molecule whose production is governed by these genes can be targets of drug therapy, Cichowski said.
Molecule called EZH2 are enzymes, and enzymes are usually always the potential for targeted therapy. According Cichowski, today many companies are developing inhibitors EZH2.
Actually this way is also done by Jer-Tsong Hsieh. Lecturer of pathology and urology at the University of Texas Southwestern Medical Center, Dallas, was researching a group of genes that are related to prostate cancer in 2002.
"We complement each other, our findings are very similar. I am a biologist examines cells and proteins, while Cichowski gene approach," Hsieh said, commenting on the findings of Harvard researchers.
Even Hsieh-led group is currently conducting research to develop a substance used in a chemical reaction to detect the enzyme.
Other prostate cancer genes researchers are Dr. Arul Chinnaiyan, professor of pathology and urology at the University of Michigan.
Research conducted Chinnaiyan of the recently published showing a link why EZH2 mechanistic trigger on cancer metastasis.
"It's quite interesting because there are a lot of interest in the world of biotechnology in developing inhibitors EZH2," Chinnaiyan added.
"Chinnaiyan has shown that there are genes for EZH2 in advanced prostate cancer," said Cichowski. "Hsieh indicated that the two genes in this genetic test is the target of EZH2 and can be attenuated by EZH2. This is one of the 250 genes targeted by EZH2. We have shown that in rat gene are the main target of EZH2 in prostate cancer."
DAB2IP named this gene is suppressed in prostate cancer, and the pressure level is correlated with cancer aggressiveness.
This is the first study that clearly shows not only genes but also the flow of metastasis in prostate cancer.
0 comments:
Post a Comment